Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | -85.71% | -85.71% | -93.33% |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharma Services
76.7
%
| - | - | 0 | 76.7 % | - |
Patient Testing Service
23.3
%
| - | - | 0 | 23.3 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | +6.85% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Director of Finance/CFO | 43 | 01/09/01 | |
Michael Ruxin
CTO | Chief Tech/Sci/R&D Officer | 78 | 01/18/01 |
Trevor McCartney
IRO | Public Communications Contact | - | 01/19/01 |
Michael Vallone
PRN | Corporate Officer/Principal | - | 09/23/09 |
Mattia Cremona
PRN | Corporate Officer/Principal | - | 07/22/07 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jeffrey Busch
CHM | Chairman | 66 | 18/20/18 |
Michael Ruxin
CTO | Chief Tech/Sci/R&D Officer | 78 | 01/18/01 |
Director of Finance/CFO | 43 | 01/09/01 | |
Danica Holley
BRD | Director/Board Member | 51 | 04/22/04 |
Yvonne Fors
BRD | Director/Board Member | 52 | 18/20/18 |
Matthew Schwartz
BRD | Director/Board Member | 50 | 05/22/05 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 500 | 0 | 0 | 17.39 % |
Stock B | 0 | 1,000 | 0 | 0 | |
Stock C | 1 | 6,151,499,919 | 1,069,660,735 ( 17.39 %) | 0 |
Company contact information
Sector
Sales per Business
1st Jan change | Capi. | |
---|---|---|
-93.33% | 4.31M | |
+8.38% | 115B | |
+10.13% | 105B | |
-11.69% | 22.71B | |
+2.21% | 21.83B | |
-10.88% | 18.18B | |
-41.90% | 16.52B | |
-16.00% | 16.01B | |
+2.28% | 14.14B | |
+20.54% | 10.71B |
- Stock Market
- Equities
- THER Stock
- Company Theralink Technologies, Inc.